CFG
HALO icon

Clayton Financial Group’s Halozyme HALO Stock Holding History

Clayton Financial Group’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17
Closed -$1.25K – 628
2025
Q3 		$1.25K Buy
+17
New +$1.13K ﹤0.01% 268

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Clayton Financial Group's HALO Position: Q4 2025 in Review

Clayton Financial Group sold out of Halozyme (HALO) in Q4 2025, closing a stake of 17 shares — an estimated $1.25K sold.

Clayton Financial Group first reported a position in HALO in Q3 2025 and held it in 1 quarter. The position peaked at $1.25K in Q3 2025. 619 funds tracked by Wall St. Rank hold HALO as of Q4 2025.

  • Clayton Financial Group reported no remaining Halozyme position as of Q4 2025 after selling out during the quarter.
  • Clayton Financial Group sold 17 Halozyme shares in Q4 2025, an estimated $1.25K.
  • Clayton Financial Group first reported a position in Halozyme in Q3 2025 and held it in 1 quarter.
  • Clayton Financial Group's Halozyme position peaked at $1.25K in Q3 2025.
  • 619 funds tracked by Wall St. Rank held Halozyme as of Q4 2025.

Based on Clayton Financial Group's 13F filing for Q4 2025, filed 21 Jan 2026.